A PANEL, RECEPTION AND INDUSTRY NETWORKING
What Are The Links Between Policy, Media and Public Perception In The Pharmaceutical industry?
From Warren Buffett to Shakespeare, business and societal leaders emphasize that a good reputation is our most valuable asset. Certainly, when reputation is lost, it can cause tremendous loss of value, both intangible and very tangible. For recent examples, look no further than Volkswagen, BP and indeed the entire banking industry.
Does the same hold true for the Pharmaceutical sector? Many firms in the sector have gone through scandals involving corruption, test data falsification, bribery and more without losing substantial traction in the markets – events which might have paralyzed other industries. How can policy have an impact on reputation.
Original research and findings developed by the media analysis and analytics firm CARMA shows that, globally, critics of the industry are growing stronger, opposition to certain practises is growing harsher and the regulatory and political attitudes persistently challenging for the industry. This conference will examine how critical reputation really is to the industry, how policy can have an impact on media and public perceptions and how to sustain strong reputational capital.
Michael Hopkins Co-author, Science, the State and the City (2016); Senior Lecturer and Director of Research, Sciene Policy Research Unit, University of Sussex
Jo Pisani Partner and Lifesciences Consulting Lead, Strategy& (Part of the PwC Network)
Ross Taylor SVP Innovation and Social Media, Digitas Health/Publicis Healthcare
Aileen Thompson Executive Director Communications, Association of the British Pharmaceutical Industry (ABPI)
Tom Vesey Managing Director, Analysis, CARMA
Have questions about "A Crisis of Trust?" Pharma, Reputation and Policy UK?
Contact Gotham Media